Tocilizumab Overcomes Chemotherapy Resistance in Mesenchymal Stem-Like Breast Cancer by Negating Autocrine IL-1A Induction of IL-6

In order to gain insight into pathways that contributed to the divergent sensitivity to chemotherapy, scientists compared the inflammatory profile of the TNBC subtypes treated with docetaxel.